Logo-npj
Submitted: 26 Oct 2023
Accepted: 12 Jan 2024
ePublished: 29 Jun 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2024;13(2): e11672.
doi: 10.34172/npj.2024.11672
  Abstract View: 121
  PDF Download: 71

Meta Analysis

A systematic review and meta-analysis of the effect of statins on osteoporotic fractures

Shahin Asgari-Savadjani ORCID logo, Maryam Tavakoli Chaleshtori ORCID logo, Mohammad Mousavi* ORCID logo

1 Department of Internal Medicine, Clinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran
*Corresponding Author: Mohammad Mousavi, Email: M_mousavi50@yahoo.com

Abstract

Introduction: Statins can increase bone density and improve osteoporosis. As fractures are the worst outcome of osteoporosis, our study aimed to investigate the relationship between statins and osteoporotic fractures using a systematic review and meta-analysis.

Materials and Methods: A systematic review and meta-analysis were conducted using the PRISMA checklist to draft this article. ProQuest, PubMed, Web of Science, Cochrane, and Google Scholar were searched to access sources without time restrictions until November 10, 2023. Data analysis was performed using STATA 14 software.

Results: About 12 studies showed that statins generally reduced osteoporotic fractures (OR: 0.82; 95% CI: 0.72, 0.94). The association between statins and osteoporotic fractures in case-control studies (OR: 0.92; 95% CI: 0.76, 1.11), RCT studies (OR: 1.67; 95% CI: 0.86, 3.26), and cohort studies (OR: 0.70; 95% CI: 0.59, 0.83) was observed. The likelihood of osteoporotic fractures with the use of pravastatin (OR: 0.96; 95% CI: 0.87, 1.07), fluvastatin (OR: 0.88; 95% CI: 0.75, 1.03), atorvastatin (OR: 0.92; 95% CI: 0.76, 1.10), rosuvastatin (OR: 0.85; 95% CI: 0.66, 1.08), and simvastatin (OR: 0.98; 95% CI: 0.92, 1.03) was noted. Additionally, statins led to a reduction in vertebral fractures (OR: 0.74; 95% CI: 0.65, 0.86) but showed no effect on the hip region (OR: 0.78; 95% CI: 0.60, 1.01). In the groups of 30–364 cumulative defined daily doses (cDDD) (OR: 0.84; 95% CI: 0.65, 1.08) and ≥365 cDDD (OR: 0.50; 95% CI: 0.25, 1), no significant association was observed between statins and osteoporotic fractures.

Conclusion: Overall, statins resulted in an 18% reduction in the risk of osteoporotic fractures.

Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023484864) and Research Registry (UIN: reviewregistry1750) website.


Implication for health policy/practice/research/medical education:

Our meta-analysis, combining the results of 12 reviewed studies, showed that statins overall prevent 18% of osteoporosis fractures and 26% of vertebral fractures, but do not have a significant effect on reducing hip fractures.

Please cite this paper as: Asgari-Savadjani S, Tavakoli Chaleshtori M, Mousavi M. A systematic review and meta-analysis of the effect of statins on osteoporotic fractures. J Nephropharmacol. 2024;13(2):e11672. DOI: 10.34172/npj.2024.11672.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 122

Your browser does not support the canvas element.


PDF Download: 71

Your browser does not support the canvas element.